Twenty-fraction cervical chemoradiation shortened treatment but raised a late GI toxicity signal
44 Gy in 20 fractions shortened cervical cancer treatment by seven days but showed numerically more severe late GI toxicity.
Tag
High relevance
SMART achieved durable local control in pancreatic cancer while distant progression dominated
After 50 Gy in five fractions, local progression was 15% at one year, while distant progression remained the dominant failure pattern.
Five-fraction SBRT better preserves quality of life before pancreatic cancer surgery
In randomized phase II SOFT Preop, five-fraction SBRT better preserved patient-reported quality of life than 28-fraction chemoradiotherapy. Pathological nodal positivity did not differ significantly, but oncologic noninferiority was not established.
Weekly cisplatin fails to reduce overall acute toxicity during head and neck chemoradiotherapy
NRG-HN009 found no reduction in overall acute grade 3-4 toxicity with weekly versus three-weekly cisplatin during definitive head and neck RT. Toxicity profiles differed, and neither phase II cohort met the criteria to proceed to phase III.
SBRT shows better 5-year patient-reported erectile function than prostatectomy in PACE-A
In PACE-A, moderate-to-severe erectile dysfunction at 5 years affected 44% of SBRT respondents vs 89% after prostatectomy. The patient-reported difference was significant, but analyses were as treated and follow-up questionnaires were incomplete.
Starting TTFields during chemoradiotherapy does not improve survival in newly diagnosed glioblastoma
TRIDENT found no OS benefit from starting TTFields during RT/TMZ rather than at maintenance in newly diagnosed glioblastoma. Median OS was 17.7 vs 17.5 months. A post hoc MGMT-methylated subgroup signal remains exploratory.
NRG-BN010 immuno-RT combination failed to improve response in recurrent glioblastoma
Tocilizumab, atezolizumab and 24 Gy/3-fraction FSRT produced only a 3.4% objective response rate in recurrent glioblastoma.
Previous pain response strongly predicted benefit from palliative reirradiation
Pain response after reirradiation was 60% in lesions that previously responded to RT versus 15% after primary nonresponse.
Short-course TNT increases pCR numerically but shows no survival advantage over long-course chemoradiotherapy
In a randomized phase III trial, short-course RT-based TNT produced a numerically higher pCR rate than long-course chemoradiotherapy, but no significant DFS, LRFS, or OS benefit emerged after 28 months of follow-up.
Adding sintilimab to short-course TNT doubles complete response in pMMR rectal cancer
In randomized STELLAR II, adding sintilimab to short-course RT-based TNT increased complete response from 26.8% to 51.9% in pMMR locally advanced rectal cancer, with higher toxicity. Three-year DFS remains pending.
Five-fraction SBRT shows excellent long-term disease control alongside prostatectomy in PACE-A
In randomized phase III PACE-A, 5-fraction SBRT and radical prostatectomy both achieved excellent long-term disease control in localized prostate cancer, with no significant efficacy difference after a median 8 years of follow-up.
SRS doubles median survival vs HA-WBRT without worsening neurocognitive failure in SCLC brain metastases
In phase III NRG-CC009, SRS did not improve neurocognitive failure vs HA-WBRT plus memantine, but median OS was 17.4 vs 8.6 months. Adjusted intracranial control, neurologic mortality, and grade 3-5 toxicity were similar.
Fractionated SRS improves surgical bed control after resection of large brain metastases
In phase III Alliance A071801, postoperative fractionated SRS improved 1-year surgical bed control to 87% vs 81% with single-fraction SRS, without significantly increasing radiation necrosis. Overall survival also favored fSRS.
Protons spare liver but do not improve survival over photons in advanced HCC
In randomized phase III NRG-GI003, protons substantially reduced non-tumor liver dose but did not improve OS, PFS, or local progression over photons in advanced HCC. Grade 3+ toxicity was numerically lower.
Three-week postmastectomy RT maintains durable locoregional control at 10 years
Ten-year CHN HYPOPMRT results show durable locoregional control and similar survival with 43.5 Gy in 15 fractions vs 50 Gy in 25 fractions after mastectomy, with no emerging severe late-toxicity signal.